SU056

SKU: orb1685600

Description

SU056 is a small molecule inhibitor targeting YB-1, disrupting its downstream signaling pathways. In vitro studies demonstrate its ability to induce cell-cycle arrest, apoptosis, and suppress migration in ovarian cancer cell lines, supporting its use in oncology research.

Research Area

Cell Biology

Key Properties

• CAS Number: 2376580-08-2
• MW: 369.34
• Purity: 99.89% (May vary between batches)
• Formula: C₂₀H₁₆FNO₅
• SMILES: OCCN1C2=C(C(c3cccc(F)c3)c3cc4OCOc4cc13)C(=O)OC2
• Target: Y Box Binding Protein 1
• Solubility: DMSO:45 mg/mL (121.84 mM)

Bioactivity

• In Vivo:
  SU056 (20 mg/kg, intraperitoneal injection) inhibits tumor growth in mice implanted with ID8 cells. SU056 (10 mg/kg, intraperitoneal injection, daily) combined with paclitaxel (5 mg/kg, weekly, intraperitoneal injection) inhibits tumor growth in immunodeficient mice implanted with ovarian cancer cells (OVCAR8), and the effect is more significant than that of single administration .
  Read more...
• In Vitro:
  SU056 ( 0-10 μ M, 48 hours) inhibits the growth of OVCAR3/4/5/8, SKOV3, and ID8 cells. SU056 (1 μ M, 5-8 days) inhibits colony formation in OVCAR-8 and ID8 cells in a dose-dependent manner. SU056 (1-5 μ M, 6 hours) blocks OVCAR8, SKOV3 and ID8 cells in sub G1 phase and G1 phase phase. SU056 (0-1 μ M, 12 hours) inhibits migration of OVCAR8, SKOV3 and ID8 cells. SU056 (0-5 μ M, 24 hours) induce apoptosis of OVCAR8, SKOV3, and ID8 cells. SU056 (1-5 μ M, 12 h) inhibits the expression of YB-1, TMSB10, SUMO2, and PMSB2 proteins in OVCAR8 cells. SU056 (0.1, 0.5, and 1 μ M. 48 hours) enhances the cytotoxic effect of paclitaxel (0.1, 0.5, and 1 nM) .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

1,3Dioxolo[4,5g]furo[3,4b]quinolin8(5H)one,9(3fluorophenyl)6,9dihydro5(2hydroxyethyl), SU056, SU-056, SU 056

Compound Identifiers

PubChem CID

155351586